Full Fed. Circ. Urged To Undo 'Extraordinary' Gilenya IP Ruling
Novartis on Thursday urged the Federal Circuit to reverse what it called "an extraordinary" ruling invalidating its patent covering its multibillion-dollar multiple sclerosis drug Gilenya, arguing that a judge's departure from...To view the full article, register now.
Already a subscriber? Click here to view full article